Biotechnology Industry - Publications - Faculty & Research - Harvard Business School

Filter Results: (402)

Filter Results: (402)

Show Results For

← Page 3 of 402 Results →

Sort by

Are you looking for?

→Search All HBS Web

December 2000
Case

Paradigm Genetics: The Industrialization of Genomics

By: Ray A. Goldberg, Carin-Isabel Knoop and Laure Mougeot Stroock

Keywords: Genetics; Biotechnology Industry

Find at Harvard

20 May 2013
Op-Ed

Making America an Industrial Powerhouse Again

computer science, optics, and various engineering disciplines. We need to get over the outdated notion that manufacturing is "mature" and unconnected to science. Anyone who believes that should take a tour of a factory that produces semiconductors or View Details

Keywords: by Gary Pisano; Manufacturing

April 2008
Teaching Note

Viagen: Revolutioning the Livestock Industry (TN)

By: David E. Bell, Mary L. Shelman and Eliot Sherman

Teaching Note for [507021]. View Details

Keywords: Investment; Genetics; Production; Training; Customers; Supply Chain; Business Plan; Commercialization; Information Technology; Performance Efficiency; Governing Rules, Regulations, and Reforms; Industry Structures; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry

January 2014 (Revised June 2015)
Teaching Note

Amgen Inc: Pursuing Innovation and Imitation? (A), (B)

By: Ian Mackenzie

Keywords: Strategic Change; Biosimilars; Medical Biotechnology; Emerging Markets; Industry Structure; Uncertainty; Strategy Development; Implementation; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States

22 Apr 2009
Working Paper Summaries

Where is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location

Keywords: by Arthur Daemmrich; Pharmaceutical

December 2014 (Revised February 2017)
Case

Simplot Plant Sciences: Designing a Better Potato

By: Jose B. Alvarez and Mary Shelman

Privately held Simplot has developed a new genetically engineered potato that substantially reduces waste and does not turn brown after cutting. Unlike other GMOs, it does not contain foreign genes. The case describes the company's commercialization plans in light of... View Details

Keywords: GMO; Sustainability; Agribusiness; Biotechnology; Food And Environment; Plant-Based Agribusiness; Food; Disruptive Innovation; Technological Innovation; Marketing; Product Positioning; Genetics; Value Creation; Agriculture and Agribusiness Industry; United States

November 2017
Case

BeiGene

By: Willy Shih and Jimmy Zhang

BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window... View Details

Keywords: Biotechnology; Pharmaceutical Company; Pharmaceuticals; China; Regulatory Environment; Business Strategy; Business Startups; Innovation Strategy; Situation or Environment; Pharmaceutical Industry; China

June 2020
Case

Breakthroughs at Blueprint Medicines

By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma

Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details

Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts

August 2013 (Revised October 2013)
Case

MedImmune Ventures

By: Richard G. Hamermesh and David Lane

Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details

Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; Australia; Europe; London

January 2018
Supplement

BeiGene Supplemental PowerPoint

By: Willy C. Shih and Jimmy Zhang

BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window... View Details

Keywords: Biotechnology; Pharmaceutical Company; Pharmaceuticals; China; Regulatory Environment; Business Strategy; Innovation Strategy; Situation or Environment; Pharmaceutical Industry; Pharmaceutical Industry; China

March 2018 (Revised May 2018)
Case

Celgene

By: Malcolm Baker and Emily McComb

In February 2011, Adam Koppel, a managing director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with... View Details

Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry

January 2021
Case

Takeda Pharmaceutical Company Limited (A)

By: David J. Collis, Nobuo Sato and Akiko Kanno

This case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition would turn... View Details

Keywords: Pharmaceutical Companies; Pharmaceuticals; Biotech; Biotechnology; M＆A; Mergers ＆ Acquisitions; R＆D; Talent Management; Mergers and Acquisitions; Globalization; Management; Global Strategy; Talent and Talent Management; Pharmaceutical Industry; Pharmaceutical Industry; Japan; Asia

01 May 2009
Conference Presentation

The enabling and constraining effects of attention structures on entrepreneurial activity in the U.S. biodiesel industry

By: Shon R. Hiatt

Keywords: Entrepreneurship; Energy Industry; Energy Industry; United States

October 2012
Teaching Plan

Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech (TP)

By: Robert F. Higgins

This is the teaching note related to HBS case 808005. In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates... View Details

Keywords: Venture Philanthropy; Biotechnology; Funding Philanthropy Venture; Cystic Fibrosis; Foundations; Pharmaceuticals; Mergers and Acquisitions; For-Profit Firms; Venture Capital; Philanthropy and Charitable Giving; Science-Based Business; Nonprofit Organizations; Pharmaceutical Industry; Pharmaceutical Industry; United States; San Diego

March 2018 (Revised May 2018)
Supplement

Celgene (B)

By: Malcolm Baker and Emily McComb

Supplements the (A) case. View Details

Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry

24 Jun 2008
Conference Presentation

The effect of heterogeneous institutional actors on entrepreneurial activity and resource attainment in the U.S. biodiesel industry

By: Shon R. Hiatt

Keywords: Entrepreneurship; Energy Industry; Energy Industry; United States

11 Oct 2009
Conference Presentation

The impact of institutional actors as attention structures on entrepreneurial activity in the U.S. biodiesel industry

By: Shon R. Hiatt

Keywords: Entrepreneurship; Energy Industry; Energy Industry; United States

January 2014
Supplement

Fred Khosravi and AccessClosure (C)

By: Richard Hamermesh and Lauren Barley

On September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the... View Details

Keywords: Medical Devices; Vascular Closure Device; Patent Litigation; Patenting; Biomedical Research; Biotechnology; Biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States

October 2013 (Revised January 2014)
Supplement

Fred Khosravi and AccessClosure (B)

By: Richard G. Hamermesh and Lauren Barley

It was January 2013, and Fred Khosravi, chairman of the board of AccessClosure Inc., wondered what the new year had in store for him and AccessClosure, the company he founded in late 2002. Khosravi was cautiously optimistic—the Mountain View, California-based medical... View Details

Keywords: Medical Devices; Vascular Closure Device; Patent Litigation; Patenting; Biomedical Research; Biotechnology; Biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States; California

January 2021
Supplement

Takeda Pharmaceutical Company Limited (B)

By: David J. Collis, Nobuo Sato and Akiko Kanno

This case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challenges Takeda and... View Details

Keywords: Pharmaceutical Companies; Pharmaceuticals; M＆A; Mergers ＆ Acquisitions; Biotech; Biotechnology; R＆D; Talent Management; Mergers and Acquisitions; Globalization; Global Strategy; Talent and Talent Management; Strategy; Biotechnology Industry; Biotechnology Industry; Japan; Asia

←
3
4
…
20
21
→